glp-1 gip therapy alternatives after discontinuation TrimRX Weight maintenance after discontinuation of

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection

Key pathways, including Wnt/-catenin, bone morphogenetic protein 2/Smad, phosphoinositide 3-kinase/Akt and protein kinase A, play a role in this

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain